RLMD
RLMD
US75955J4022
Relmada Therapeutics, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
361.61M EUR
738.16M EUR
730.04M EUR
354.2M EUR
Enterprise Value
120.41M EUR
726.82M EUR
720.26M EUR
350.7M EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-8.27x
--
--
--
Price to Sales
--
--
--
--
Price to Book
1.75x
3.57x
3.34x
4.09x
EV/Revenue
--
--
--
--
EV/EBITDA
--
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-6.54%
-6.23%
-5.86%
-7.83%
ende